First Light Asset Management LLC Acquires 16,573 Shares of AnaptysBio, Inc. $ANAB

First Light Asset Management LLC increased its holdings in shares of AnaptysBio, Inc. (NASDAQ:ANAB) by 2.9% in the second quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 582,004 shares of the biotechnology company’s stock after buying an additional 16,573 shares during the period. AnaptysBio accounts for about 2.4% of First Light Asset Management LLC’s investment portfolio, making the stock its 17th biggest holding. First Light Asset Management LLC owned approximately 1.97% of AnaptysBio worth $39,285,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds have also modified their holdings of ANAB. AQR Capital Management LLC lifted its holdings in AnaptysBio by 153.3% in the first quarter. AQR Capital Management LLC now owns 30,011 shares of the biotechnology company’s stock valued at $558,000 after buying an additional 18,165 shares during the period. Creative Planning grew its holdings in AnaptysBio by 26.9% during the 2nd quarter. Creative Planning now owns 16,854 shares of the biotechnology company’s stock worth $374,000 after acquiring an additional 3,571 shares during the period. JPMorgan Chase & Co. grew its holdings in AnaptysBio by 1,631.6% during the 2nd quarter. JPMorgan Chase & Co. now owns 247,625 shares of the biotechnology company’s stock worth $5,497,000 after acquiring an additional 233,325 shares during the period. Russell Investments Group Ltd. bought a new stake in shares of AnaptysBio during the 2nd quarter valued at $528,000. Finally, Arrowstreet Capital Limited Partnership acquired a new position in shares of AnaptysBio in the 2nd quarter valued at $3,348,000.

AnaptysBio Stock Down 1.6%

Shares of NASDAQ ANAB opened at $55.70 on Thursday. The company’s fifty day moving average is $57.59 and its 200-day moving average is $59.27. The stock has a market cap of $1.65 billion, a price-to-earnings ratio of -51.57 and a beta of 0.71. AnaptysBio, Inc. has a twelve month low of $11.40 and a twelve month high of $72.36.

Analysts Set New Price Targets

ANAB has been the topic of several recent research reports. Wall Street Zen lowered AnaptysBio from a “strong-buy” rating to a “hold” rating in a research report on Saturday, May 16th. Leerink Partners set a $90.00 price objective on AnaptysBio in a report on Friday, May 15th. Wolfe Research reissued an “outperform” rating and issued a $78.00 target price on shares of AnaptysBio in a research note on Monday, August 31st. Barclays raised their target price on AnaptysBio from $63.00 to $75.00 and gave the stock an “overweight” rating in a report on Wednesday, May 13th. Finally, Zacks Research lowered AnaptysBio from a “strong-buy” rating to a “hold” rating in a research report on Tuesday, June 2nd. Eleven investment analysts have rated the stock with a Buy rating, three have given a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat.com, AnaptysBio currently has a consensus rating of “Moderate Buy” and an average price target of $79.85.

AnaptysBio Profile

AnaptysBio, Inc is a clinical-stage biotechnology company focused on the discovery and development of therapeutic antibody product candidates in immunology and inflammation. Founded in 2012 and headquartered in San Diego, California, AnaptysBio leverages a proprietary somatic hypermutation platform to rapidly generate and refine human antibodies with optimized efficacy and safety profiles. The company’s technology is designed to accelerate target validation and candidate selection across a range of immune-mediated conditions.

The company’s pipeline includes multiple clinical-stage programs addressing dermatological and inflammatory disorders.